Monoclonal antibodies as therapeutic agents in oncology and antibody gene therapy

被引：43

作者：

Zhang, Qi

Chen, Guihua

Liu, Xinyuan

Qian, Qijun

机构：

[1] Second Mil Med Univ, Western Hepatobiliary Surg Hosp, Lab Viral & Gene Therapy, Shanghai 200438, Peoples R China

[2] Sun Yat Sen Univ, Affiliated Hosp 3, Transplantat Res Inst, Guangzhou 510630, Guangdong, Peoples R China

[3] Chinese Acad Sci, Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China

来源：

CELL RESEARCH | 2007年 / 17卷 / 02期

关键词：

monoclonal antibody; cancer; gene therapy;

D O I：

10.1038/sj.cr.7310143

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Antibodies as therapeutic agents are mostly used in oncology, as illustrated by their applications in lymphoma, breast cancer or colorectal cancer. This review provides a brief historical sketch of the development of monoclonal antibodies for cancer treatment and summarizes the most significant clinical data for the best-established reagents to date. It also discusses strategies to improve the anti-tumor efficacy of antibody therapy, including antibody gene therapy and exploitation of bone marrow derived primary mesenchymal stem cells as the antibody gene transporter.

引用

页码：89 / 99

页数：11

共 63 条

[1] Pharmacokinetics and biodistribution of genetically engineered antibodies [J].

Batra, SK ;

Jain, M ;

Wittel, UA ;

Chauhan, SC ;

Colcher, D .

CURRENT OPINION IN BIOTECHNOLOGY, 2002, 13 (06) :603-608

[2] Therapeutic applications of monoclonal antibodies [J].

Berger, M ;

Shankar, V ;

Vafai, A .

AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2002, 324 (01) :14-30

[3] Improving the efficacy of antibody-based cancer therapies [J].

Carter, P .

NATURE REVIEWS CANCER, 2001, 1 (02) :118-129

[4] Modulation of tumor growth by inhibitory Fcγ receptor expressed by human melanoma cells [J].

Cassard, L ;

Cohen-Solal, JFG ;

Galinha, A ;

Sastre-Garau, X ;

Mathiot, C ;

Galon, J ;

Dorval, T ;

Bernheim, A ;

Fridman, WH ;

Sautès-Fridman, C .

JOURNAL OF CLINICAL INVESTIGATION, 2002, 110 (10) :1549-1557

[5] Engineering antibodies for clinical applications in cancer [J].

Chester, K ;

Pedley, B ;

Tolner, B ;

Violet, J ;

Mayer, A ;

Sharma, S ;

Boxer, G ;

Green, A ;

Nagl, S ;

Begent, R .

TUMOR BIOLOGY, 2004, 25 (1-2) :91-98

[6] Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease [J].

Cobleigh, MA ;

Vogel, CL ;

Tripathy, D ;

Robert, NJ ;

Scholl, S ;

Fehrenbacher, L ;

Wolter, JM ;

Paton, V ;

Shak, S ;

Lieberman, G ;

Slamon, DJ .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2639-2648

[7] Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J].

Cunningham, D ;

Humblet, Y ;

Siena, S ;

Khayat, D ;

Bleiberg, H ;

Santoro, A ;

Bets, D ;

Mueser, M ;

Harstrick, A ;

Verslype, C ;

Chau, I ;

Van Cutsem, E .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) :337-345

[8]

CUNNINGHAM D, 2003, P AN M AM SOC CLIN, V22, P1012

[9]

CZUCZMAN M, 2003, ASH ANN M ABSTR, V102, P1493

[10] Immunochernotherapy in indolent non-Hodgkin's lymphoma [J].

Czuczman, MS .

SEMINARS IN ONCOLOGY, 2002, 29 (02) :11-17

← 1 2 3 4 5 6 7 →